- Home
- DBRG vs ARQT Comparison
DBRG vs ARQT Comparison
Compare DBRG & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBRG | ARQT |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DBRG | ARQT |
|---|---|---|
| Price | $15.88 | $25.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $16.00 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 4.4M | 2.2M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ 557.14 | 88.79 |
| EPS | ★ 1.18 | 0.03 |
| Revenue | $93,959,000.00 | ★ $376,072,000.00 |
| Revenue This Year | $373.39 | $34.85 |
| Revenue Next Year | $8.23 | $29.39 |
| P/E Ratio | ★ $13.48 | $887.33 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $8.94 | $16.68 |
| 52 Week High | $15.98 | $31.77 |
Technical Indicators
Market Signals| Indicator | DBRG | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 53.44 |
| Support Level | $15.33 | $24.91 |
| Resistance Level | $15.92 | $27.57 |
| Average True Range (ATR) | 0.04 | 1.12 |
| MACD | -0.01 | 0.32 |
| Stochastic Oscillator | 30.77 | 67.67 |
Price Performance
Historical ComparisonAbout DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.